Scarica l'app Stockscreener
12.45
1.75%
0.1547
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$12.30
Aprire:
$12.05
Volume 24 ore:
1.61M
Relative Volume:
0.61
Capitalizzazione di mercato:
$1.42B
Reddito:
-
Utile/perdita netta:
$-242.30M
Rapporto P/E:
-5.0221
EPS:
-2.48
Flusso di cassa netto:
$-192.10M
1 W Prestazione:
+8.83%
1M Prestazione:
+73.10%
6M Prestazione:
+52.62%
1 anno Prestazione:
+44.02%
Intervallo 1D:
$12.01
$12.74
Intervallo di 1 settimana:
$11.60
$12.97
Portata 52W:
$3.72
$12.97
Cogent Biosciences Inc Stock (COGT) Company Profile
Nome
Cogent Biosciences Inc
Settore
Industria
Telefono
617-945-5576
Indirizzo
275 WYMAN STREET, WALTHAM
Confronta COGT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
COGT
Cogent Biosciences Inc
|
12.51 | 1.55B | 0 | -242.30M | -192.10M | -2.48 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.31 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
556.33 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.77 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
573.86 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.62 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
Cogent Biosciences Inc Stock (COGT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-07 | Iniziato | Scotiabank | Sector Outperform |
| 2024-12-11 | Downgrade | Needham | Buy → Hold |
| 2024-02-26 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-02-08 | Iniziato | Citigroup | Buy |
| 2023-12-11 | Downgrade | Wedbush | Outperform → Neutral |
| 2023-12-08 | Iniziato | JP Morgan | Overweight |
| 2023-04-28 | Iniziato | Robert W. Baird | Outperform |
| 2023-03-27 | Ripresa | H.C. Wainwright | Buy |
| 2022-12-14 | Iniziato | Needham | Buy |
| 2022-06-28 | Iniziato | Guggenheim | Buy |
| 2021-10-11 | Iniziato | H.C. Wainwright | Buy |
| 2021-06-09 | Ripresa | Jefferies | Buy |
| 2020-12-23 | Iniziato | Piper Sandler | Overweight |
| 2020-10-14 | Iniziato | Ladenburg Thalmann | Buy |
Mostra tutto
Cogent Biosciences Inc Borsa (COGT) Ultime notizie
What analysts say about Cogent Biosciences Inc. stockOutstanding investment returns - jammulinksnews.com
Cogent Biosciences (NASDAQ:COGT) Given New $22.00 Price Target at Citigroup - MarketBeat
3 Stocks With Sky-High Overbought Signals: QuantumScape, Opendoor, Cogent Flash RSI Red Flags - Benzinga
When (COGT) Moves Investors should Listen - news.stocktradersdaily.com
Is Cogent Biosciences Inc. a good long term investmentBreakout portfolio performance - Autocar Professional
Cogent Biosciences Inc. Stock Analysis and ForecastOutperformance with explosive growth - Autocar Professional
What drives Cogent Biosciences Inc. stock priceDouble-digit growth - jammulinksnews.com
Cogent Biosciences (COGT) Target Price Raised by Citigroup | COG - GuruFocus
Cogent Biosciences stock hits 52-week high at 12.66 USD By Investing.com - Investing.com South Africa
Cogent Biosciences stock hits 52-week high at 12.66 USD - Investing.com
Blueprint Medicines' (BPMC) Ayvakit Faces Competition from Cogent Biosciences | BPMC Stock News - GuruFocus
Blueprint Medicines' (BPMC) Ayvakit Faces Competition from Cogen - GuruFocus
Jefferies Raises Cogent Biosciences (COGT) PT, Keeps Buy Rating - MSN
Cogent Biosciences: Analyst Maintains Buy Rating Amid Promising Trials and Strategic Advantages - AInvest
Day 11 of Gains Streak for Cogent Biosciences Stock with 67% Return (vs. 52% YTD) [7/16/2025] - Trefis
10 Best Small-Cap Stocks to Buy According to Billionaires - Insider Monkey
COGT Stock Up 62% after 10-Day Win Streak - Trefis
Mintz Advises on Cogent Biosciences’ $230 Million Public Offering - Mintz
Press Release: Cogent Biosciences Announces Proposed $150 Million Public Offering of Common Stock - 富途牛牛
COGT Stock Soars on Phase III Systemic Mastocytosis Study Success - MSN
Cogent Biosciences (NASDAQ:COGT) Stock Price Expected to Rise, Jefferies Financial Group Analyst Says - MarketBeat
Guggenheim Reiterates "Buy" Rating for Cogent Biosciences with $17 Price Target - AInvest
Cogent Biosciences (NASDAQ:COGT) Price Target Raised to $22.00 at HC Wainwright - MarketBeat
Cogent Biosciences Closes $230 Million Upsized Stock Offering - MarketScreener
Cogent Biosciences Announces Closing of Upsized Public Offering of Shares of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares - The Manila Times
Cogent Biosciences Announces Closing of Upsized Public - GlobeNewswire
Cogent Biosciences Secures Massive $230M Funding for Bezuclastinib Drug Development - Stock Titan
Cogent Biosciences’ Mysterious 5.6% Surge: What’s Behind the Move? - AInvest
Cogent Biosciences' 8% Surge: Unraveling the Mystery Behind the Spike - AInvest
Cogent Biosciences(COGT) Soars 6.34% on Phase III Success - AInvest
Form 424B5 Cogent Biosciences, Inc. - StreetInsider
Cogent: Positive Data In NonAdvSM Bodes Well For 2nd Half AdvSM Treatment Results (COGT) - Seeking Alpha
Cogent Biosciences: Drug Trial Triumph Sparks Stock Surge - StocksToTrade
A Quick Look at Today's Ratings for Cogent Biosciences(COGT.US), With a Forecast Between $17 to $25 - 富途牛牛
Cogent Biosciences slips after upsized $200 mln equity offering - TradingView
Cogent Biosciences Prices $200 Million Stock Offering - MarketScreener
Cogent Biosciences (COGT) Prices $200M Public Offering at $9 Per Share - GuruFocus
Cogent Biosciences Scores Analyst Praise As Mastocytosis Drug Hits Trial Goals; Retail Buzz Surges - NewsBreak: Local News & Alerts
Cogent Biosciences Secures Massive $200M Funding to Accelerate Bezuclastinib Development - Stock Titan
Cogent Biosciences Announces Pricing of Upsized Public Offering of Shares of Common Stock - The Manila Times
Cogent Biosciences announces pricing of upsized public offering of shares of common stock - MarketScreener
Cogent Biosciences Announces Pricing of Upsized Public Offering of Shares of Common Stock | COGT Stock News - GuruFocus
Cogent Biosciences stock falls on $150 million share offering By Investing.com - Investing.com India
After-hours movers: Mobileye, RxSight, Cogent Biosciences By Investing.com - Investing.com Canada
Cogent Biosciences (COGT) Sees Positive Analyst Action with Rais - GuruFocus
Cogent's Funding to Propel Bezuclastinib Development | COGT Stoc - GuruFocus
Cogent Biosciences' $150M Offering: A Risky Gamble or a Strategic Bet on Breakthrough Science? - AInvest
Cogent Biosciences stock falls on $150 million share offering - Investing.com Australia
Cogent Biosciences Announces Proposed $150 Million Public Offering of Common Stock - The Manila Times
Cogent Biosciences Inc Azioni (COGT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Cogent Biosciences Inc Azioni (COGT) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Pinnow Cole | Chief Commercial Officer |
Jan 14 '25 |
Buy |
7.60 |
43,750 |
332,412 |
45,848 |
0.54%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):